{"id":"aegr-733","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal effects (diarrhea, steatorrhea, abdominal discomfort)"},{"rate":null,"effect":"Elevated liver transaminases"},{"rate":null,"effect":"Fat-soluble vitamin deficiency"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting MTP, AEGR-733 decreases the assembly and secretion of VLDL and chylomicrons from the liver and intestine, leading to reduced plasma levels of triglycerides and LDL cholesterol. This mechanism is particularly relevant for severe hypertriglyceridemia and familial chylomicronemia syndrome, where elevated triglycerides pose a risk of acute pancreatitis.","oneSentence":"AEGR-733 is a microsomal triglyceride transfer protein (MTP) inhibitor that reduces the production and secretion of apolipoprotein B-containing lipoproteins.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:00:08.054Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Familial chylomicronemia syndrome (Type I hyperlipoproteinemia)"},{"name":"Severe hypertriglyceridemia"}]},"trialDetails":[{"nctId":"NCT06832371","phase":"","title":"Evaluation of the Effect of Lomitapide Treatment on Major Adverse Cardiovascular Events (MACE) in Patients With Homozygous Familial Hypercholesterolemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)","startDate":"2024-09-09","conditions":"Homozygous Familial Hypercholesterolemia (HoFH), Major Adverse Cardiovascular Events (MACE), Dyslipidemia","enrollment":73},{"nctId":"NCT04681170","phase":"PHASE3","title":"Efficacy and Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH)","status":"COMPLETED","sponsor":"Amryt Pharma","startDate":"2020-12-14","conditions":"Homozygous Familial Hypercholesterolaemia (HoFH)","enrollment":46},{"nctId":"NCT02135705","phase":"","title":"LOWER: Lomitapide Observational Worldwide Evaluation Registry","status":"RECRUITING","sponsor":"Amryt Pharma","startDate":"2014-03-18","conditions":"Homozygous Familial Hypercholesterolemia","enrollment":300},{"nctId":"NCT02399839","phase":"","title":"Global Lomitapide Pregnancy Exposure Registry","status":"TERMINATED","sponsor":"Amryt Pharma","startDate":"2014-10","conditions":"Pregnancy","enrollment":5},{"nctId":"NCT01915771","phase":"PHASE1","title":"Study to Determine the Intra-subject Variability of Pharmacokinetics of Lomitapide in Healthy Subjects","status":"COMPLETED","sponsor":"Aegerion Pharmaceuticals, Inc.","startDate":"2013-07-29","conditions":"Intra-subject Variability of Pharmacokinetics","enrollment":15},{"nctId":"NCT02080455","phase":"PHASE1","title":"Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Lomitapide in Healthy Subjects.","status":"COMPLETED","sponsor":"Aegerion Pharmaceuticals, Inc.","startDate":"2014-01-27","conditions":"Effect of Atorvastatin on the Pharmacokinetics of Lomitapide","enrollment":32},{"nctId":"NCT02080468","phase":"PHASE1","title":"Evaluate the Effect of Ethinyl Estradiol/Norgestimate on the Pharmacokinetics of Lomitapide in Healthy Female Subjects","status":"COMPLETED","sponsor":"Aegerion Pharmaceuticals, Inc.","startDate":"2014-02-19","conditions":"Healthy","enrollment":32},{"nctId":"NCT01760187","phase":"PHASE1","title":"Phase I Study of the Safety, Tolerability, PK & PD of Lomitapide in Japanese and Caucasian Subjects With Elevated LDL-C","status":"COMPLETED","sponsor":"Aegerion Pharmaceuticals, Inc.","startDate":"2012-11-07","conditions":"Healthy Volunteer","enrollment":72},{"nctId":"NCT02173158","phase":"PHASE3","title":"Efficacy and Safety of Lomitapide in Japanese Patients With HoFH on Concurrent Lipid-Lowering Therapy","status":"COMPLETED","sponsor":"Aegerion Pharmaceuticals, Inc.","startDate":"2014-04-02","conditions":"Familial Hypercholesterolemia - Homozygous","enrollment":9},{"nctId":"NCT00943306","phase":"PHASE3","title":"Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Aegerion Pharmaceuticals, Inc.","startDate":"2009-10-29","conditions":"Familial Hypercholesterolemia","enrollment":19},{"nctId":"NCT00474240","phase":"PHASE2","title":"AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia","status":"COMPLETED","sponsor":"Aegerion Pharmaceuticals, Inc.","startDate":"2007-04","conditions":"Hypercholesterolemia","enrollment":157},{"nctId":"NCT00730236","phase":"PHASE3","title":"A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)","status":"COMPLETED","sponsor":"Aegerion Pharmaceuticals, Inc.","startDate":"2007-12","conditions":"Homozygous Familial Hypercholesterolemia","enrollment":29},{"nctId":"NCT00690443","phase":"PHASE2","title":"Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia","status":"COMPLETED","sponsor":"Aegerion Pharmaceuticals, Inc.","startDate":"2008-05","conditions":"Hypercholesterolemia","enrollment":44},{"nctId":"NCT00559962","phase":"PHASE2","title":"Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS","status":"COMPLETED","sponsor":"Aegerion Pharmaceuticals, Inc.","startDate":"2007-10","conditions":"Hyperlipidemia","enrollment":260},{"nctId":"NCT00359281","phase":"PHASE2","title":"Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents","status":"COMPLETED","sponsor":"Aegerion Pharmaceuticals, Inc.","startDate":"2006-03","conditions":"Healthy","enrollment":125},{"nctId":"NCT02765841","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of Lomitapide in Pediatric Patients With Homozygous Familial Hypercholesterolemia on Stable Lipid-lowering Therapy","status":"WITHDRAWN","sponsor":"Aegerion Pharmaceuticals, Inc.","startDate":"2016-05","conditions":"Homozygous Familial Hypercholesterolemia","enrollment":""},{"nctId":"NCT02044419","phase":"PHASE1","title":"A Comparative Bioavailability Study of Lomitapide 20 mg Intact vs Sprinkled","status":"COMPLETED","sponsor":"Aegerion Pharmaceuticals, Inc.","startDate":"2013-10-30","conditions":"Healthy","enrollment":32},{"nctId":"NCT02399852","phase":"","title":"Effects of Lomitapide on Carotid and Aortic Atherosclerosis","status":"WITHDRAWN","sponsor":"Aegerion Pharmaceuticals, Inc.","startDate":"2015-06","conditions":"Homozygous Familial Hypercholesterolemia","enrollment":""},{"nctId":"NCT00405067","phase":"PHASE2","title":"The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia","status":"COMPLETED","sponsor":"Aegerion Pharmaceuticals, Inc.","startDate":"2006-05","conditions":"Hypercholesterolemia","enrollment":60},{"nctId":"NCT01556906","phase":"PHASE2","title":"Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) Inhibitor","status":"COMPLETED","sponsor":"Aegerion Pharmaceuticals, Inc.","startDate":"2003-06","conditions":"Homozygous Familial Hypercholesterolemia","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["lomitapide","BMS-201038"],"phase":"phase_3","status":"active","brandName":"AEGR-733","genericName":"AEGR-733","companyName":"Aegerion Pharmaceuticals, Inc.","companyId":"aegerion-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AEGR-733 is a microsomal triglyceride transfer protein (MTP) inhibitor that reduces the production and secretion of apolipoprotein B-containing lipoproteins. Used for Familial chylomicronemia syndrome (Type I hyperlipoproteinemia), Severe hypertriglyceridemia.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2013-07-31T00:00:00.000Z","mah":"Chiesi Farmaceutici SpA","brand_name_local":"Lojuxta","application_number":"EMEA/H/C/002578"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}